Evidence map›Paper›PMID 33519490›Full record

ArticleFrontiers in pharmacology2020

The Selective SIK2 Inhibitor ARN-3236 Produces Strong Antidepressant-Like Efficacy in Mice via the Hippocampal CRTC1-CREB-BDNF Pathway.

Yue Liu, Wenqian Tang, Chunhui Ji, Jianghong Gu, Yanmei Chen, Jie Huang, Xinyi Zhao, Yingfang Sun, Chengniu Wang, Wei Guan and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. A female-specific role for Slit1 in prenatal stress-induced depression vulnerability.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Aminothioneine, a product derived from golden oyster mushrooms (Biochemistry and biophysics reports · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yue LiuDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Wenqian TangDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Chunhui JiDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Jianghong GuDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Yanmei ChenDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Jie HuangDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Xinyi ZhaoDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Yingfang SunDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Chengniu WangBasic Medical Research Centre, Medical College, Nantong University, Nantong, China.
Wei GuanDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Jianfeng LiuDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Bo JiangDepartment of Pharmacology, School of Pharmacy, Nantong University, Nantong, China.
Nantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Depression is a widespread chronic medical illness affecting thoughts, mood, and physical health. However, the limited and delayed therapeutic efficacy of monoaminergic drugs has led to intensive research efforts to develop novel antidepressants. ARN-3236 is the first potent and selective inhibitor of salt-inducible kinase 2 (SIK2). In this study, a multidisciplinary approach was used to explore the antidepressant-like actions of ARN-3236 in mice. Chronic social defeat stress (CSDS) and chronic unpredictable mild stress (CUMS) models of depression, various behavioral tests, high performance liquid chromatography-tandem mass spectrometry, stereotactic infusion, viral-mediated gene transfer, western blotting, co-immunoprecipitation and immunofluorescence were used together. It was found that ARN-3236 could penetrate the blood-brain barrier. Repeated ARN-3236 administration induced significant antidepressant-like effects in both the CSDS and CUMS models of depression, accompanied with fully preventing the stress-enhanced SIK2 expression and cytoplasmic translocation of cyclic adenosine monophosphate response element binding protein (CREB)-regulated transcription coactivator 1 (CRTC1) in the hippocampus. ARN-3236 treatment also completely reversed the down-regulating effects of CSDS and CUMS on the hippocampal brain-derived neurotrophic factor (BDNF) system and neurogenesis. Moreover, we demonstrated that the hippocampal CRTC1-CREB-BDNF pathway mediated the antidepressant-like efficacy of ARN-3236. Collectively, ARN-3236 possesses strong protecting effects against chronic stress, and could be a novel antidepressant beyond monoaminergic drugs.

Indexed as

ARN-3236brain-derived neurotrophic factorCREB-Regulated transcription coactivator 1cyclic AMP response element binding proteindepressionhippocampussalt-inducible kinase 2

Identifiers

PMID33519490
PMCPMC7840484
OpenAlexW3118991171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.